TargED Biopharmaceuticals B.V.
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $5.1Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2025-06-30attributed |
| Founded | unknown |
| Headquarters | Biopharmaceuticals |
| Industry | biotechnology |
| Stage | unknown |
| Website | targedbio.com |
TargED develops targeted thrombolytic drugs that use small VHH antibodies to deliver clot-dissolving enzymes directly to a thrombus. It targets patients with thrombotic disorders such as acute ischemic stroke and iTTP. Its differentiator is localized enzyme delivery that works regardless of clot composition.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-30 | grant | $2.7M | undisclosed |
Detected tech stack
WordPress, Yoast SEO 27.6, Underscore.js 1.13.8, Font Awesome, jQuery Migrate 3.4.1, jsDelivr, Varnish, OpenResty, Nginx, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $5.1M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | targedbio.com, read 2026-05-08 |
| Description | self-reported | targedbio.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.